Curriculum Vitae


  • Department of Medicine
    Faculty of Medicine
  • +603-79502741




  • MMED(2005) (UM), (Perubatan Dalaman (Internal Medicine))
    Universiti Malaya (UM)
  • MD(UKM)(1998), (Medicine)
    Universiti Kebangsaan Malaysia (UKM)


  • Organizer for fellowship exam on behalf of Malaysian Society of Haematology
    28 Nov 2012 - present (National)
  • Planning on call and monthly duty roster of medical department
    01 Jan 2010 - present (Department of Medicine, Faculty of Medicine)
  • Coordinator
    11 Aug 2011 - 05 Jan 2023 (Department of Medicine, Faculty of Medicine)
  • Coordinator
    01 Sep 2015 - 05 Jan 2023 (Department of Medicine, Faculty of Medicine)
  • Quality Manager
    17 Jan 2012 - 31 Dec 2022 (Department of Medicine, Faculty of Medicine)
  • Acting Treasurer
    10 Sep 2020 - 30 Apr 2022 (National)
  • Head of Unit
    08 Feb 2019 - 08 Jan 2021 (Department of Medicine, Faculty of Medicine)
  • Acting Chairman
    09 Sep 2020 - 09 Oct 2020 (National)
  • Acting Chairman
    01 Jan 2020 - 12 Sep 2020 (National)
  • Chairman
    01 Jan 2020 - 10 Sep 2020 (National)
  • Chairman
    01 Jul 2019 - 04 Apr 2020 (National)


  • First research subject
    Novotech, 2019 (International)
    University of Malaya, 2019 (University)
    University of Malaya, 2018 (University)
    University of Malaya, 2013 (University)
  • Geran sanjungan penyelidikan
    Ministry of higher education, 2012 (Government)
  • Best poster presentation in Malaysian Society of Haematology meeting 2008
    Malaysian Society of Haematology, 2008 (National)


Article in Journal
  1. Ting, Choo-Yuen; Tan, Soo-Yong; Gan, Gin-Gin; Zain, Shamsul-Mohd; Pung, Yuh-Fen; Ong, Diana Bee-Lan; Bee, Ping-Chong (2022). Downregulation of hsa-miR-548d-3p and overexpression of HOXA9 in diffuse large B-cell lymphoma patients and the risk of R-CHOP chemotherapy resistance and disease progression, INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY. 44(5), 907-917. doi:10.1111/ijlh.13928
  2. Anuar, N. A., Tey, K. W. F., Ng, S. C., Teh, A. K. H., Rahman, M., Chong, B. P., & Gan, G. G. (2021). Outcomes of high dose therapy and autologous haematopoietic stem cell transplantation for non-hodgkin lymphoma: A retrospective analysis in a resource-limited country. International Journal of Clinical Practice, 75(3), 7. doi: 10.1111/ijcp.13823
  3. Efficace, F., Iurlo, A., Patriarca, A., Stagno, F., Bee, P. C., Ector, G., . . . Rosti, G. (2021). Validation and reference values of the EORTC QLQ-CML24 questionnaire to assess health-related quality of life in patients with chronic myeloid leukemia. Leukemia & Lymphoma, 62(3), 669-678. doi: 10.1080/10428194.2020.1838509
  4. Lim, J. L., Ng, E. Y., Lim, S. Y., Tan, A. H., Abdul-Aziz, Z., Ibrahim, K. A., . . . Ahmad-Annuar, A. (2021). Association study of MCCC1/LAMP3 and DGKQ variants with Parkinson's disease in patients of Malay ancestry. Neurological Sciences, 42(10), 4203-4207. doi: 10.1007/s10072-021-05056-x
  5. Cappellini, M. D., Viprakasit, V., Taher, A. T., Georgiev, P., Kuo, K. H. M., Coates, T., . . . Investigators, B. (2020). A Phase 3 Trial of Luspatercept in Patients with Transfusion-Dependent beta-Thalassemia. New England Journal of Medicine, 382(13), 1219-1231. doi: 10.1056/NEJMoa1910182
  6. Tan, B. K., Chua, S. S., Chen, L. C., Chang, K. M., Balashanker, S., & Bee, P. C. (2020). Efficacy of a medication management service in improving adherence to tyrosine kinase inhibitors and clinical outcomes of patients with chronic myeloid leukaemia: a randomised controlled trial. Supportive Care in Cancer, 28(7), 3237-3247. doi: 10.1007/s00520-019-05133-0
  1. Ting C.-Y., Tan S.-Y., Gan G.-G., Zain S.-M., Pung Y.-F., Ong D.B.-L., Bee P.-C. (2022). Downregulation of hsa-miR-548d-3p and overexpression of HOXA9 in diffuse large B-cell lymphoma patients and the risk of R-CHOP chemotherapy resistance and disease progression, International Journal of Laboratory Hematology. 44(5), 907-917. doi:10.1111/ijlh.13928
  1. Kevin-Tey, W. F., Wen, W. X., Bee, P. C., Eng, H. S., Ho, K. W., Tan, S. M., ... & Zain, S. M. (2022). KIR genotype and haplotype frequencies in the multi-ethnic population of Malaysia. Human Immunology.
  2. Monitoring and improving adherence to tyrosine kinase inhibitors in patients with chronic myeloid leukemia: a systematic review
  3. A phase 3 trial of luspatercept in patients with transfusion-dependent -thalassemia MD Cappellini, V Viprakasit, AT Taher, P Georgiev, KHM Kuo, T Coates, ... New England Journal of Medicine 382 (13), 1219-1231
  4. A rare case of metastatic lung carcinoma with t (15; 19)(q13; p13. 1) and trisomy 12 KT Za, PC Bee, H Shanmugam Pathology 52 (2), 273-276
  5. Acceptability of pharmacist-led interventions to resolve drug-related problems in patients with chronic myeloid leukaemia BK Tan, SS Chua, LC Chen, KM Chang, S Balashanker, PC Bee Journal of Oncology Pharmacy Practice, 1078155220964539
  6. Anuar NA, Tey KWF, Ng SC, Teh AKH, Abdul Rahman MHF, Chong BP, Gan GG. (2020) Outcomes of high dose therapy and autologous haematopoietic stem cell transplantation for non-hodgkin lymphoma: A retrospective analysis in a resource-limited country. Int J Clin PractNov 17:e13823. doi: 10.1111/ijcp.13823.
  7. Efficacy of a medication management service in improving adherence to tyrosine kinase inhibitors and clinical outcomes of patients with chronic myeloid leukaemia: a randomised BK Tan, SS Chua, LC Chen, KM Chang, S Balashanker, PC Bee SUPPORTIVE CARE IN CANCER 28 (7), 3249-3249
  8. Extranodal site of diffuse large B cell lymphoma and the risk of R CHOP chemotherapy resistance and early relapse CY Ting, GG Gan, D Bee Lan Ong, SY Tan, PC Bee International journal of clinical practice 74 (10), e13594
  9. Jackson N, Khairullah S, Bee PC (2020) Luspatercept-induced reduction in transfusion requirement in alpha-thalassaemia.eJHaem, 2020;1: 297-299.
  10. Time in therapeutic range, quality of life and treatment satisfaction of patients on long-term warfarin for non-valvular atrial fibrillation: a cross-sectional study NMBA Malik, CS Chai, SB Tan, PC Bee, GG Gan, AB Said Health and quality of life outcomes 18 (1), 1-9
  11. Validation and Reference Values of the EORTC QLQ-CML24 Questionnaire to Assess Health-Related Quality of Life in Patients with Chronic Myeloid Leukemia .Leukemia & Lymphoma. 1-10
  12. DLC Ng, GG Gan, CS Chai, KH Chee, KL Tan, SB Tan, PC Bee. Comparing quality of life and treatment satisfaction between patients on warfarin and direct oral anticoagulants: a cross-sectional study. Patient Prefer Adherence. 2019; 13: 1363 1373. doi: 10.2147/PPA.S204246
  13. GG Gan, Diana LC Ng, YC Leong, PC Bee, EFM Chin, AH Habibah, TA Hidayat, H Loo, AKH The. Anxiety and depression in patients with haematological neoplasms in Malaysia. Med J Malaysia 2019;74:191-97
  14. HY Ting P Sthaneshwar PC Bee H Shanmugam M Lim (2019) Heavy/light chain assay in the monitoring of multiple myeloma. Pathology, 51(5), 507-11.
  15. Genotype-guided versus traditional clinical dosing of warfarin in patients of Asian ancestry: a randomized controlled trial
  16. bee kim Tan et al. 2017:11 1027 1034
  17. An isodicentric (X)(q13) abnormality. Tay Za Kyaw, Kok-siong Chen, Josephine Pasangna, Ping Chong Bee. Southeast Asian of case report.
  18. The predictive value of early molecular response in chronic myeloid leukaemia patients treated with imatinib in a single real world medical centre in a developing country. Bee Ping Chong, Richard Ng Rui Jie, Veera Sekaran, Kweh Ting Yi, Gan Gin Gin. Accepted by Singapore medical Journal in November 2015.
  19. Thoracic aortic aneurysm mimicking primary haematological disorder: A case report. Mohamed Nazrulhisham Mad Naser, Bee ping chong, Nor Khairiah A. Karim. Case report in internal medicine. vol 3, No 4,2016
  20. Influence of genetic polymorphisms of cytokine genes in the outcome of HLA-matched allogeneic stem cell transplantation in a South East Asian Population. G.G. Gan , Y.C. Leong, P.C. Bee, E.F.M. Chin, H. Abdul Halim, V.S. Nadarajan, A.K.H. Teh . Cytokine 78 (2016) 55 61.
  21. . Effect of polymorphisms within methotrexate pathway genes on methotrexate toxicity and plasma levels in adults with hematological malignancies. Suthandiram S1, Gan GG, Zain SM, Bee PC, Lian LH, Chang KM, Ong TC, Mohamed Z. Pharmacogenomics. 2014 Aug;15(11):1479-94. doi: 10.2217/pgs.14.97.
  22. Impact of Inadequate Doses of Rituximab in the Treatment of Diffuse Large B Cell Lymphoma in Malaysian Patients Gin Gin Gan*, Rajaletchumy Subramaniam, Ping Chong Bee, Edmund Fui Min Chin, Habibah Abdul-Halim, Mei Chee Tai
  23. Polymorphisms in methylenetetrahydrofolate reductase gene and risk of non-Hodgkin lymphoma in a multi-ethnic population Sujatha Suthandiram1, Gin Gin Gan2, Shamsul Mohd Zain1, Batoul Sadat Haerian1, Ping Chong Bee2, Lay Hoong Lian3, Kian Meng Chang4, Tee Chuan Ong4 and Zahurin Mohamed1
  24. Helicobacter pylori infection in chronic immune thrombocytopenic purpura patients in Malaysia G G Gan, FRCP, Norfaizal A L, MMed, P C Bee, MMed, E F M Chin, MMed, Habibah A H, MRCP, K L Goh, FRCP
  25. Lim SK, Bee PC, Keng TC, Chong YB. Resolution of epoetin-induced pure red cell aplasia two years later, successful re-challenge with continuous erythropoiesis receptor stimulator. Clinical Nephrology 2012.
  26. Survey of Willingness to Accept Chemotherapy among Elderly Malaysian Patients Rizah Mazzuin Razali, Ping Chong Bee*, Gin Gin Gan
  27. Acquired Factor VIII inhibitors: a description of three different cases
  28. An Update on Imatinib Mesylate Therapy in Chronic Myeloid Leukaemia Patients in a Teaching Hospital in Malaysia Singapore Medical Journal
  29. Increased lipocalin-2 and diminished SOCS3 gene expression occur on appearance of chronic myeloid leukemia phenotype in a patient with concurrent JAK2- V617F and BCR-ABL mutation
  30. nadarajan VS, Ang CH, Syed-Sultan MK, Bee PC Imatinib resistance and blast transformation of chronic myeloid leukemia associated with a novel tri-nucleotide insertion mutation of BCR-ABL kinase domain at position K294 Annals of Hematology. 2011 Mar 26.
  31. Bullous Pemphigoid in an Elderly with Myelodysplastic Syndrome and Refractory Anemia with Excess Blast. Yin Yin Lee, Ping chong Bee, Chew Kek Lee,Manimalar Naicker,Rokiah Ismail.
  32. Quality of Life after Haematopoietic Stem Cell Transplantation in a Multiracial Population.The Medical Journal of Malaysia
  33. Tay Za Kyaw, S. Jayaranee, Ping Chong Bee Chin Edmund Fui Min,Veera Sekaran Nadarajan turkish journal of hematologyMyeloid. Sarcoma: An unusual presentation of Acute Promyelocytic Leukaemia causing spinal cord compression.
  34. Veera S Nadarajan, 1 Chin-Lee Phan, 1,2 Chow-Hiang Ang, 1 Kai-Ling Liang, 1 Gin-Gin Gan, 3 Ping-Chong Bee, 3 Zubaidah Zakaria4Identification of copy number alterations by array comparative genomic hybridization in patients with late chronic or accelerated phase chronic myeloid leukemia treated with imatinib mesylate. . Int J Hematol DOI 10.1007/s12185-011-0796-9
  35. GG Gan1, ME Phipps2, MT Lee3, L- S Lu3, Subramaniam R1, PC Bee1, SH Chang4 Contribution of VKORC1 and CYP2C9 polymorphisms in the interethnic variability of warfarin dose in Malaysian populations. . Ann Hematol DOI 10.1007/s00277-010-1119-6
  36. PC Bee, GG Gan, VS Nadarajah,NA.Latiff, N. Menaka. A Man with Concomitant Polycythaemia Vera and Chronic Myeloid Leukemia: The Dynamic of the Two Disorders. Int J Hematol. 2010 Jan;91(1):136-9. Epub 2010 Jan 5
  37. GG Gan, Z Zakaria, JV Sangkar, AR Haris, PC Bee, E Chin, A Teh. Adult Allogeneic haematopoietic Stem Cell transplantation: A Single Centre Experience in Malaysia. Med J Malaysia 2008 Oct;63(4):281-7
  38. PC Bee, G G Gan, VJ Sangkar, Haris Abd Rahman Nephrotic Syndrome in a Patient with Relapsed of Chronic Myeloid Leukemia after Peripheral Blood Stem cell Transplantation. . Med Journal of Malaysia, March 2008.
  39. Bee PC, Gan G G, Haris ABD R, Zanapiah Z , Wan Azman Comparison of Portable Device and standard laboratory measured INR in University Malaya Medical Centre. ASEAN Heart Journal 15 (2 ) July 2007
  40. PC Bee, GG Gan, A Teh, A R Haris Imatinib Mesylate in the Treatment of Chronic Myeloid Leukaemia: A Local Experience, Med J Malaysia Vol 61 No. 5 December 2006
  41. P.C. Bee, G.G. Gan, J.V. Sangkar, A. The, K.Y. Goh,A Case of T-cell Acute Lymphoblastic Lymphoma/Leukaemia after Treatment of Acute Promyelocytic Leukaemia, International Journal of Hematology 79 (2004) 358-360.
  42. PC Bee, SK Chow, LH Tan. A Case of Severe Leptospirosis with Pancytopenia, Med J Malaysia Vol 58 No 5 December 2003.
Article in Proceeding
  1. Improvements to detection of BCR-ABL1 kinase domain mutations in patients with chronic myeloid leukemia on tyrosine kinase inhibitors using high resolution melt curve analysis
  2. PC Bee, GG Gan Ting TY, Haris AR, E Chin, Habibah AH, Nadarajan VS. An Update on Imatinib Mesylate Therapy in Chronic Myeloid Leukaemia Patients in a Teaching Hospital in Malaysia. First Asean federation of Haematology and 8th National haematology ,pg 80 scientific meeting, April 2010,pg 80


  1. 2019 - 2024, Monash University
    Asia Pacific Myeloma and related diseases registry ( Co-Researcher)
  2. 2011 - 2013, Geran Penyelidikan Universiti Malaya (UMRG)
    The Influence of Gene Polymorphism in Malaysian Populition For Folate Metabolizing Enzymes With Respect To Toxicity in Hon Hodhkin Lymphoma and Acute Lymphoblastic Leukemia Patients Treated With Methotrexate ( Principal Investigator(PI))
  3. 2008 - 2010, Norvatis
    CAAMN107A2109 Trial. An open-label, multicenter, expanded access study of oral AMN 107 in adult patients with imatinib (Glivec/Gleevec)-resistant or-intolerant chronic myeloid leukaemia in blast crisis, accelerated phase or chronic phase. ( Consultant)
  1. 2020 - 2028, Novartis Corporation (M) Sdn. Bhd.
    A randomized, double-blind, placebo-controlled phase III multi-center study of azacitidine with or without MBG453 for the treatment of patients with intermediate, high or very high risk myelodysplastic syndrome (MDS) as per IPSS-R, or Chronic Myelomonocytic Leukemia-2 (CMML-2) ( Co-Researcher)
  2. 2019 - 2027, Celgene Corporation
    A Phase 3b, open-label, single-arm, rollover study to evaluate long-term safety in subjects who have participated in other luspatercept (ACE-536) clinical trials ( Principal Investigator(PI))
  3. 2021 - 2026, MorphoSys AG
    A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL) ( Principal Investigator(PI))
  4. 2022 - 2025, NS Pharma, Inc
    A Phase 2b, Open-label, Multicenter, Randomized, Controlled, 2-Arm Study to Assess the Efficacy and Safety of Orally Administered NS-018 versus Best Available Therapy in Subjects with Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis with Severe Thrombocytopenia (Platelet Count <50,000/ L) ( Co-Researcher)
    Randomized Phase 3 study of Pomalidomide-Cyclophosphamide-Dexamethasone (PCD) versus Pomalidomide-Dexamethasone (PD) in relapse or refractory myeloma. An AMN study ( Co-Researcher)
  6. 2016 - 2019, Private Funding
    A phase 3, double blind,randomized ,placebo-controlled ,multicenter study to determine the efficacy and safety of luspatercept (ACE-536) versus placebo in adults who required regular red blood cell transfusions due to beta thalassemia (ACE-536-B-THAL-001 ( Principal Investigator(PI))
  7. 2015 - 2018, International Funding
    A multicenter, randomised,open-label,three-parallel groups,phase 2-3 study to evaluate the efficacy and safety of masitinib with dexamethasone,gemcitabine with dexamethasone and the combination of masitinib,gemcitabine and dexamethasone in patients with relapsed or refractory peripheral T-cell lymphoma ( Principal Investigator(PI))
  8. 2013 - 2015, NONE
    PNH registry ( Principal Investigator(PI))
  9. 2012 - 2014, NONE
    SANDOZ GP13-301 -A Randomized, Controlled, Double- Blind Phase III Trial in Patients with Previously Untreated, Advanced Stage Follicular Lymphoma ( Principal Investigator(PI))
  10. 2008 - 2013, Johnson & Johnson Pharmaceutical Research & Development
  11. 2008 - 2010, Pfizer
    A Phase III, Double Blind, Randomized Study To Evaluate Safety And Efficacy Of BAL8557 Versus Voriconazole For Primary Treatment Of Invasive Fungal Disease Caused By Aspergillus Species Or Other Filamentous Fungi ( Consultant)
    A Phase 3, Randomized, Double-blind, Active-Control Study of Pelabresib (CPI-0610) and Ruxolitinib vs. Placebo and Ruxolitinib in JAKi Treatment Naive MF Patients ( Co-Researcher)
  2. 2022 - 2023, AstraZeneca Sdn. Bhd.
    A Multicenter Retrospective Study To Understand The Clinical Characteristics, Treatment Pathway And Resource Utilization For Patients With Chronic Lymphocytic Leukemia (CLL). ( Principal Investigator(PI))


  1. Overview of Haploidentical HSCT: Local Experience(UMMC), Malaysian Society of Transplant Annual meeting 2022, MST (National) (28 May 2022 - 29 May 2022)
  2. treatment of cutaneous lymphoma, updates in haematological malignancies, Medical department (National) (16 Nov 2019 - 16 Nov 2019)
  3. Acute Graft versus Host disease: How to prevent and treat?, The 5th ASEAN Federation of Hematology conference 2019, Indonesian Society of Hematology (International) (01 Nov 2019 - 02 Nov 2019)
  4. Life long anticoagulant, College of physician regional conference 2019-updates in internal medicine, Academy of Medicine , Malaysia (National) (21 Jun 2019 - 23 Jun 2019)
  5. Follicular Lymphoma: What are the current treatment strategies?, 16th Malaysian Society of Haematology Scientific meeting, Malaysian Society of Haematology (National) (11 Apr 2019 - 13 Apr 2019)
  6. High Dose Chemotherapy/Autologous Haematopoietic Stem Cell Transplantation(ASCT), Master Class in Systemic Cancer Therapy , oncology department (National) (15 Mar 2019 - 16 Mar 2019)
  7. mutiple myeloma, speaker at the B-Cell Malignancies Update for the Health Care Alliance, December 5th 2015 (National) (05 Dec 2015 - 05 Dec 2015)
  8. Early Complications of Allo-HSCT other than Graft vs Host Disease (GvHD), Art of Haematology 2015, 17-18th October 2015 (International) (17 Oct 2015 - 18 Oct 2015)
  9. Bone marrow transplantation, Oncology workshop in UMMC, 30th May 2015 (University) (30 May 2015 - 30 May 2015)
  10. Managing bleeding with NOACs, NOAC (University) (30 May 2015 - 30 May 2015)
  11. Chronic myeloid leukaemia, patient workshop (National) (14 Jun 2014 - 14 Jun 2014)
  12. Multiple myeloma, 4th Patient Congress for People Living with Blood Cancer - 6 April 2014, Hotel, Kuala Lumpur (National) (06 Apr 2014 - 06 Apr 2014)
  13. Should quality of life be a therapeutic endpoint, Malaysian society of haematology 2014 Scientific Meeting at Shangri-La Hotel, 4 6 April 2014.  (National) (04 Apr 2014 - 06 Apr 2014)
  14. Massive splenomegaly , Advances in internal Medicine 2014, UPM (National) (16 Feb 2014)
  15. Multiple myeloma, Patient congress (multiple myeloma), Max foundation (National) (28 Apr 2013 - 28 Apr 2013)
  16. Lecture/Tutorial on Haematology, Saturday teaching in Haematology, Academy of Medicine (National) (12 May 2012)
  17. Approach to adult patients with anaemia, weekend teaching, Academy of Medicine , Academy of medicine (National) (08 Jan 2011 - 08 Jan 2011)
  18. Multiple Myeloma & CRAB, The Spectrum Workshop (for GP) (National) (24 Apr 2009 - 26 Apr 2009)
  19. Management of anticoagulation, INR Clinic Workshop, UMMC (University) (19 Jul 2008)
  20. Perioperative anticoagulation management, 1st National Anticoagulation Management Workshop 2007 (National) (11 Aug 2007)
  1. workshop, Oragnising committee for Transfusion workshop in UMMC (National) (21 Aug 2015 - 22 Aug 2015)
  2. scientific meeting, Ornanising committee of MSH 2015 scientific meeting, 24-25th April (National) (24 Apr 2015 - 26 Apr 2015)
  3. Scientific meeting, Organising committee of MSH 2014 Scientific Meeting, 4-6 April (04 Apr 2014 - 06 Apr 2014)
  4. multiple myeloma, Multiple myeloma and caregivers workshop (National) (22 Jun 2013 - 22 Jun 2013)
  5. Overview of Chronic Myeloid Leukaemia in UMMC, Maximize Life Workshop 23rd May 2009 (National) (23 May 2009)
  1. Case presentation, 8th New Horizons in Haematology , Shire (International) (21 Sep 2013 - 21 Sep 2013)
  2. tyrosine kinase inhibitor-first targeted agent in oncology, CPC, UMMC (University) (08 Dec 2010 - 08 Dec 2010)


  1. (2022) External Assessor for Promotion At Usm, National, (External Assessor)
  2. (2022) External Examiner of Research Project of Imu, National, (External Examiner)
  3. (2022) Evaluator, University, (Internal Evaluator)
  4. (2022) External Assessor for Promotion At Unimas, National, (External Examiner)
  5. (2022) Reviewer of Article, International, (Reviewer)
  6. (2022) Committee of National Specialist Registry for Clinical Haematology, National, (External Evaluator)
  7. (2022) Reviewer of Article, International, (Reviewer)
  8. (2022) Reviewer of Article, International, (Reviewer)
  9. (2022) Committee of National Specialist Registry, Sub Specialty (Haematology), National, (External Evaluator)
  10. (2021) Reviewer, International, (Reviewer)
  11. (2021) Educational Modules for Hcp, 18th December 2020 31st January 2021 and Virtual, National, (Reviewer)
  12. (2021) Reviewer, International, (Reviewer)
  13. (2021) Honorary Editorial Advisor, National, (Reviewer)
  14. (2021) External Assessor for Promotion of Universiti Sains Malaysia, National, (External Assessor)
  15. (2021) Reviewer, International, (Reviewer)
  16. (2021) Evaluator for New Drug Registration/Approval, National, (External Evaluator)
  17. (2021) Reviewer, International, (Reviewer)
  18. (2021) Reviewer, International, (Reviewer)
  19. (2020) Evaluate New Drug Application (Npra), National, (External Evaluator)
  20. (2020) Reviewer for Article, International, (Reviewer)
  21. (2020) Reviewer of Article, International, (Reviewer)
  22. (2020) Master of Internal Medicine, Thesis Exam, University, (Internal Examiner)
  23. (2020) External Assessor for a Research Project of Imperial College UK, International, (External Assessor)
  24. (2020) Examiner, University, (Internal Examiner)
  25. (2020) External Examiner for Phd Thesis of University of Mauritius, International, (External Examiner)
  26. (2019) drug control authority , reviewing new drug marketing application , (Reviewer)
  27. (2019) evaluate the qualification of staff that applied for promotion to associate professor , (Reviewer)
  28. (2019) judging the best poster, (Judge of poster competition)
  29. (2019) neurology Asia, (Reviewer)
  30. (2015) External assessor for new appointment of Lecturer for UKM 2015, (external assesor)
  31. (2014) Poster Judge. State research day, Ampang Hospital. 10-Nov-2014 , (Scientific Committee)
  32. (2014) Assessor for Best book award MAPIM-KPM 2013, (Reviewer)
  33. (2013) Circulating plasma RNA as a diagnostic tool to monitor treatment response and early detection of relapse in chronic myeloid leukemia, (External Examiner)
Contribution to external organisation
  1. (2022) Member of National Specialist Registry, (Hematology ), National, (Resource Person)
  2. (2020) Chief Examiner, National, (Academic Appointment )
  3. (2014) Reviewer for the Malaysian Journal of Pathology 2015, Malaysian Society of pathology
  4. (2013) Independent expert, Medical Research and ethics committee, Ministry of Health
Contribution to event
  1. (2021) Chairperson of a Talk, International, (Panelist/Moderator)
  2. (2021) Chairperson of a Talk (by Bms/Celgene), International, (Panelist/Moderator)
  3. (2021) Advisor for Asia Area Consensus Meeting - Hemato-Oncology, International, (Panelist/Moderator)
  4. (2021) Expert Input/Opinion for Chronic Lymphocytic Leukemia, International, (Panelist/Moderator)
  5. (2021) Speaker, University, (Panelist/Moderator)
  6. (2021) Speaker, University, (Panelist/Moderator)
  7. (2021) Chairperson for Webinar (by Janssen & Janssen), National, (Panelist/Moderator)
  8. (2020) Speaker, National, (Panelist/Moderator)
  9. (2020) Speaker, National, (Panelist/Moderator)
  10. (2020) Speaker, University, (Panelist/Moderator)
  11. (2020) Speaker, University, (Panelist/Moderator)


Postgraduate Student
PhD/ Doctoral
  1. (2018) Dysregulated microRNA Expression in R-CHOP Resistance/ Early Relapse of Diffuse Large B-Cell Lymphoma, Ting choo yuen
  4. (2012) Survey of Compliance of Iron Chelator In Thalassaemia Patients, Norashikin Saidon
  5. (2012) Prevalence of Cardiomyopathy Post CHOP/CHOP like chemotherapy, Doreen Sumpat
  6. (2012) Master in internal medicine, Lim Yik shen
  7. (2012) Anaemia in geriatric patient, Liong Chee Chiat
  8. (2011) Master in Internal medicine, vijayan
  9. (2010) Quality of life haematopoietic stem cell transplantation patients, Henning Loo
  10. (2010) Idiopathis thrombocytopenic purpura, Khoo Voon Ling
  11. (2010) Fungal infection in neutropenic patients, Ting Seng Kiat
  12. (2008) Autologous peripheral blood stem cell collection: factors that influences the yield of stem cells at UMMC, Dr Nor Faizal Latif
Under Graduate Students


  • Organizing Multiple Myeloma Workshop for Patients and Caregivers, (15 Aug 2015 - 15 Aug 2015)
  • Speaker in Haematology Update 2012 On 24 March 2012 (by Malaysian Society of Haematology, (24 Mar 2012 - 24 Mar 2012)
  • Speaker for Multiple Myeloma Patients Workshop, 10 September 2011., (10 Sep 2011 - 10 Sep 2011)
  • Organized Maximize Life Workshop (Cml Patients Support Group) On 5th March 2011., (05 Mar 2011 - 05 Mar 2011)
  • Conducted Haematology Workshop On 8th January 2011, Academy of Medicine Malaysia., (08 Jan 2011 - 08 Jan 2011)
  • Participate in Free Clinic At Detention Camp (Seminyih), (01 Jan 2006 - 01 Jul 2009)